ESTRO 2024 - Abstract Book

S1904

Clinical - Mixed sites, palliation

ESTRO 2024

progression was almost half less in the SBRT group (22.2% [8 of 36]) than in the cEBRT group (41.9% [13 of 31]), P=0.09.

The actuarial estimates of overall survival at 12 months was 62.1% (95% CI, 45.1-79.1%) after SBRT and 60.0% (95% CI, 41.3-78.7%) after cEBRT (hazard ratio 1.1; 95% CI 0.52 to 2.31, P=.79). At the time of analysis, radiological progression at the treated site was observed in 1 of 32 evaluable lesions (3.1%) after SBRT and in 2 of 25 evaluable lesions (8.0%) after cEBRT (P=0.42). There were no differences in treatment-induced adverse events after SBRT vs cEBRT during treatment and follow up. No radiation-induced myelopathy or plexopathy was reported. Five vertebral compression fractures were reported in the SBRT group and four in the cEBRT group during the follow-up.